Amrubicin
Topoisomerase Inhibitor
DB06263
Approved Indication
Investigated for use/treatment in lung cancer.
1
Targets
0
Resistance Mutations
2
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
As an anthracycline, amrubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: amrubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
Details
DrugBank ID
DB06263 ↗
Approval Date
—
Molecular Weight
483.473 g/mol
Drug Class
Topoisomerase Inhibitor
ATC Codes
L01DB10
Synonyms
—
PubChem
CID: 3035016 ↗
ChEMBL
CHEMBL1186894 ↗
SMILES
[H][C@@]1(C[C@@](N)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O)O[C@H]1C[C@H](O)[C@H](O)CO1
ADMET Profile
Computing properties…
Drug References (DrugBank)